title: Maslinic acid, a triterpenic anti-tumoural agent, interferes with cytoskeleton protein expression in HT29 human colon-cancer cells.
abstract: Maslinic acid (MA) is an anti-tumoural agent which shows potent anti-proliferative properties against the HT29 colon-cancer cells. To shed light upon the active mechanism of MA we have investigated its effects upon the cytoskeleton. We used a proteomics procedure based on two-dimensional gel electrophoresis, mass analysis and peptide mass fingerprinting. The incubation of HT29 cells with MA led to G1 cell-cycle arrest. After 24hours' exposure to 3.7μM (IC50/8) and 30μM (IC50) MA fourteen differentially expressed cytoskeletal proteins could be discerned. One group of these proteins, made up of keratin 2, keratin 8, keratin type II cytoskeletal 8, keratin type I cytoskeletal 9, keratin type I cytoskeletal 18, cytokeratins 18 and 19, and β-actin, exert a structural function, whilst another group, made up of lamin B1, gelsolin 1, septin 2, villin 1, actin-related protein 2 and moesin, is related to the nucleation of actin and cytoskeleton formation. Changes in the expression of moesin, villin 1 and β-actin identified by the proteomics techniques were corroborated by Western blotting. This is the first evidence obtained of the regulatory effects of MA on the cytoskeleton, which may prove to be one of the bases of its anti-proliferative effect against colon-cancer cells.
  
  
  CONCLUSIONS
  In this paper we describe the changes in the expression of different cytoskeleton proteins identified by the proteomics techniques and corroborated by Western blotting. This is the first evidence obtained of the regulatory effects of MA on the cytoskeleton, which may prove to be one of the bases of its anti-proliferative effect against colon-cancer cells.
authors.affiliation: Department of Biochemistry and Molecular Biology I, Faculty of Sciences, University of Granada, Campus Fuentenueva, 18001 Granada, Spain.
authors.forename: Eva E
authors.initials: EE
authors.lastname: Rufino-Palomares
authors.forename: Fernando J
authors.initials: FJ
authors.lastname: Reyes-Zurita
authors.forename: Leticia
authors.initials: L
authors.lastname: García-Salguero
authors.forename: Khalida
authors.initials: K
authors.lastname: Mokhtari
authors.forename: Pedro P
authors.initials: PP
authors.lastname: Medina
authors.forename: José A
authors.initials: JA
authors.lastname: Lupiáñez
authors.forename: Juan
authors.initials: J
authors.lastname: Peragón
mesh_terms: D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology*; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D003110:Colonic Neoplasms / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D003598:Cytoskeletal Proteins / Q000096:biosynthesis*; D059585:G1 Phase Cell Cycle Checkpoints / Q000187:drug effects; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects*; D006801:Humans; D009363:Neoplasm Proteins / Q000096:biosynthesis*; D014315:Triterpenes / Q000494:pharmacology*; D009828:Oleanolic Acid / Q000031:analogs & derivatives
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D003598:Cytoskeletal Proteins; D009363:Neoplasm Proteins; D014315:Triterpenes; C412811:maslinic acid; D009828:Oleanolic Acid